Key Points Novo Nordisk's business is well-equipped to rebound in the GLP-1 market. Vertex is set to launch a couple of new medicines in the next few years. Both stocks look attractively valued relative to their growth potential. 10 stocks we like better than Novo Nordisk › There are plenty of attractive stocks on the market. Some, though, have significantly underperformed their growth potential this year, making them attractive at their current levels. This list includes Novo Nordisk (NYSE: NVO ...